Ondine Biomedical, Inc.(DE:VF5)
€0.09+0.00 (+4.71%)
DE:VF5
Ondine Biomedical, Inc. financials statements
€0.09
At close:+0.00 (+4.71%)
Ondine Biomedical, Inc. (VF5) Ratios
2 Followers
Ondine Biomedical, Inc. Ratios
DE:VF5's free cash flow for Q2 2026 was C$-13.27M. For the 2026 fiscal year, DE:VF5's free cash flow was decreased by C$-111.64K and operating cash flow was C$-13.16M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 1.23 | 2.05 | 1.36 | 3.87 | 8.54 |
| Quick Ratio | 1.06 | 1.84 | 1.06 | 3.54 | 8.27 |
| Cash Ratio | 0.98 | 1.64 | 0.85 | 3.36 | 7.74 |
| Solvency Ratio | -2.66 | -3.12 | -3.79 | -3.83 | -11.06 |
| Operating Cash Flow Ratio | -2.21 | -2.61 | -3.91 | -4.18 | -3.20 |
| Short-Term Operating Cash Flow Coverage | -76.53 | 0.00 | 0.00 | 0.00 | -25.23 |
| Net Current Asset Value | C$ 2.37M | C$ 6.24M | C$ 1.10M | C$ 10.20M | C$ 29.02M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.03 | 0.01 | 0.09 | 0.05 | 0.02 |
| Debt-to-Equity Ratio | 0.12 | 0.02 | 0.26 | 0.08 | 0.02 |
| Debt-to-Capital Ratio | 0.11 | 0.02 | 0.21 | 0.07 | 0.02 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 4.13 | 1.86 | 2.75 | 1.42 | 1.15 |
| Debt Service Coverage Ratio | -88.32 | -393.32 | -362.82 | -628.30 | -28.30 |
| Interest Coverage Ratio | -1427.14 | -413.70 | -389.61 | -625.43 | -14.46 |
| Debt to Market Cap | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 |
| Net Debt to EBITDA | 0.35 | 0.52 | 0.18 | 0.65 | 0.61 |
| Profitability Margins | |||||
| Gross Profit Margin | 41.19% | 64.47% | 58.44% | 44.98% | 48.81% |
| EBIT Margin | -1132.54% | -929.77% | -1194.85% | -3031.66% | -1902.41% |
| EBITDA Margin | -1110.24% | -902.20% | -1146.05% | -2954.39% | -1882.41% |
| Operating Profit Margin | -1132.54% | -948.95% | -1230.67% | -2940.91% | -681.98% |
| Pretax Profit Margin | -1115.53% | -932.06% | -1198.00% | -3036.36% | -1949.59% |
| Net Profit Margin | -1115.53% | -932.06% | -1198.00% | -3036.36% | -1949.59% |
| Continuous Operations Profit Margin | -1115.53% | -932.06% | -1198.00% | -3036.36% | -1949.59% |
| Net Income Per EBT | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| EBT Per EBIT | 98.50% | 98.22% | 97.35% | 103.25% | 285.87% |
| Return on Assets (ROA) | -205.50% | -148.95% | -251.34% | -116.92% | -146.70% |
| Return on Equity (ROE) | -848.01% | -277.71% | -691.22% | -166.37% | -168.88% |
| Return on Capital Employed (ROCE) | -836.69% | -282.74% | -659.76% | -148.18% | -57.98% |
| Return on Invested Capital (ROIC) | -769.72% | -276.00% | -563.79% | -144.10% | -56.77% |
| Return on Tangible Assets | -205.50% | -148.95% | -251.34% | -116.92% | -146.70% |
| Earnings Yield | -39.39% | -44.18% | -49.56% | -29.67% | -27.11% |
| Efficiency Ratios | |||||
| Receivables Turnover | 5.76 | 3.99 | 3.69 | 3.51 | 10.36 |
| Payables Turnover | 1.50 | 0.46 | 0.37 | 0.90 | 1.09 |
| Inventory Turnover | 0.86 | 0.57 | 0.47 | 0.27 | 1.24 |
| Fixed Asset Turnover | 2.49 | 3.43 | 1.27 | 0.45 | 4.27 |
| Asset Turnover | 0.18 | 0.16 | 0.21 | 0.04 | 0.08 |
| Working Capital Turnover Ratio | 0.61 | 0.55 | 0.19 | 0.03 | -1.15 |
| Cash Conversion Cycle | 247.29 | -66.05 | -117.90 | 1046.26 | -3.90 |
| Days of Sales Outstanding | 63.38 | 91.38 | 98.91 | 104.12 | 35.24 |
| Days of Inventory Outstanding | 426.64 | 637.75 | 778.18 | 1345.61 | 294.50 |
| Days of Payables Outstanding | 242.72 | 795.18 | 994.99 | 403.48 | 333.63 |
| Operating Cycle | 490.02 | 729.13 | 877.09 | 1449.73 | 329.73 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.05 | -0.06 | -0.07 | -0.08 | -0.06 |
| Free Cash Flow Per Share | -0.05 | -0.06 | -0.07 | -0.09 | -0.06 |
| Dividend Paid and CapEx Coverage Ratio | -203.81 | -1549.00 | -77.14 | -52.56 | -162.86 |
| Capital Expenditure Coverage Ratio | -203.81 | -1549.00 | -77.14 | -52.56 | -162.86 |
| Operating Cash Flow Coverage Ratio | -57.81 | -92.20 | -25.24 | -18.24 | -16.97 |
| Operating Cash Flow to Sales Ratio | -9.01 | -7.56 | -11.35 | -25.62 | -4.88 |
| Free Cash Flow Yield | -31.98% | -35.86% | -47.56% | -25.51% | -6.83% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -2.54 | -2.25 | -2.02 | -3.37 | -3.69 |
| Price-to-Sales (P/S) Ratio | 28.32 | 21.10 | 24.17 | 102.33 | 71.91 |
| Price-to-Book (P/B) Ratio | 21.53 | 6.29 | 13.95 | 5.61 | 6.23 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -3.13 | -2.79 | -2.10 | -3.92 | -14.64 |
| Price-to-Operating Cash Flow Ratio | -3.14 | -2.79 | -2.13 | -3.99 | -14.73 |
| Price-to-Earnings Growth (PEG) Ratio | 0.28 | 0.53 | 0.08 | 0.05 | -0.02 |
| Enterprise Value Multiple | -2.21 | -1.82 | -1.93 | -2.81 | -3.21 |
| Enterprise Value | 64.95M | 33.63M | 26.64M | 53.06M | 155.12M |
| EV to EBITDA | -2.21 | -1.82 | -1.93 | -2.81 | -3.21 |
| EV to Sales | 24.49 | 16.41 | 22.14 | 83.16 | 60.38 |
| EV to Free Cash Flow | -2.70 | -2.17 | -1.93 | -3.19 | -12.29 |
| EV to Operating Cash Flow | -2.72 | -2.17 | -1.95 | -3.25 | -12.37 |
| Tangible Book Value Per Share | 0.01 | 0.03 | 0.01 | 0.06 | 0.15 |
| Shareholders’ Equity Per Share | 0.01 | 0.03 | 0.01 | 0.06 | 0.15 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 0.01 | 0.01 | 0.01 | 0.00 | 0.01 |
| Net Income Per Share | -0.06 | -0.07 | -0.07 | -0.10 | -0.26 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 0.98 | 1.00 | 1.00 | 1.00 | 1.02 |
| Research & Development to Revenue | 8.02 | 4.50 | 4.27 | 9.84 | 1.94 |
| SG&A to Revenue | 3.71 | 5.37 | 6.66 | 17.10 | 5.05 |
| Stock-Based Compensation to Revenue | 0.00 | 0.59 | 0.53 | 2.26 | 1.58 |
| Income Quality | 0.81 | 0.81 | 0.95 | 0.84 | 0.25 |
Currency in CAD
